Purpura, Thrombocytopaenic, Idiopathic Clinical Trial
Official title:
A Three Part, Staggered Cohort, Open-label and Double Blind, Randomized, Placebo Controlled Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of Eltrombopag, a Thrombopoietin Receptor Agonist, in Previously Treated Pediatric Patients With Chronic ITP.
Phase II, multi-center, 3 part, staggered cohort, open-label and double blind, randomized, placebo controlled study involving 3 age-determined cohorts (Cohort 1: between 12 and 17 years old; Cohort 2: between 6 and 11 years old; Cohort 3: between 1 and 5 years old). Daily dosing with eltrombopag will begin with 5 patients in the oldest age cohort in an open label fashion, and a review of safety, pharmacokinetic and platelet count data will be performed regularly. If no safety concerns are identified after 12 weeks, 18 additional patients will be randomised to placebo or eltrombopag (2:1 randomisation). After 7 weeks of randomized treatment, all patients will receive eltrombopag in an open label fashion. The total duration of treatment with eltrombopag will be 24 weeks. If at the time of the aforementioned 12 week review of the first 5 patients no safety issues are identified, dosing will begin in the next lower age cohort with an initial group of 5 patients. The same procedure will be followed in terms of safety review and subsequent enrolment and randomisation of the additional patients. Initiation of the younger age cohort will take place once data from the previous has been evaluated. Doses will be adjusted according to platelet counts and tolerability. The study will include a review of the safety data by a Data Safety Monitoring Board.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT00442871 -
Study Of SB-497115 in Healthy Subjects and Subjects With Mild, Moderate or Severe Renal Impairment
|
Phase 1 | |
| Completed |
NCT01098487 -
A Longitudinal 2-year Bone Marrow Study of Eltrombopag in Previously Treated Adults, With Chronic Immune (Idiopathic) Thrombocytopenic Purpura (ITP)
|
Phase 4 | |
| Withdrawn |
NCT01440361 -
A Study to Investigate Belimumab for the Treatment of Chronic Immune Thrombocytopenia.
|
Phase 2 | |
| Completed |
NCT01064336 -
Promacta Pregnancy Registry
|
N/A | |
| Completed |
NCT00424177 -
Repeated Exposure to Eltrombopag in Adults With Idiopathic Thrombocytopenic Purpura (REPEAT)
|
Phase 2 | |
| Completed |
NCT00351468 -
EXTEND (Eltrombopag Extended Dosing Study)
|
Phase 3 | |
| Completed |
NCT00688272 -
Study In Healthy Subjects To Evaluate The Photo-Irritant Potential Of Eltrombopag
|
Phase 1 | |
| Completed |
NCT01072162 -
Relative Bioavailibilty for Pediatric Powder for Suspension (PfOS) Formulation and Food Effect
|
Phase 1 | |
| Completed |
NCT00643929 -
LENS - Long-term Eltrombopag Observational Study
|
N/A | |
| Completed |
NCT00102739 -
SB-497115 (Oral Thrombopoietin Receptor Agonist) Versus Placebo In Adults With Refractory Immune Thrombocytopenic Purpura (ITP)
|
Phase 2 | |
| Completed |
NCT01416311 -
Drug Use Investigation for REVOLADE (ITP)
|
||
| Completed |
NCT00359463 -
Study Of Eltrombopag in Healthy Subjects and Volunteers With Mild, Moderate or Severe Hepatic Impairment
|
Phase 1 |